Within NCATS, MRIGlobal Awarded “CRO Support for NCATS Drug Substance and Development”
Kansas City, Mo. – MRIGlobal today announced the award of a five-year year program from the National Institutes of Health (NIH) National Center for Advancing Translational Sciences (NCATS). The Program will support the Division of Pre-Clinical Innovation (DPI) efforts for pre-clinical drug development.
Within NCATS, the DPI plans and conducts advanced collaborative research projects across the pre-clinical phases of translational science.
MRIGlobal will supply services related to synthesis and analysis of small molecules, and will provide support for manufacture and analysis of small molecules; process chemistry optimization; API (active pharmaceutical ingredients) characterization; analytical method validation; and controlled stability studies.
“MRIGlobal is honored to continue our support of the important work within NCATS to develop new therapies,” said Thomas M. Sack, Ph.D., President and Chief Executive Officer. “We anticipate task orders this fall.”
This project is funded in whole or in part with Federal funds from the National Center for Advancing Translational Sciences at the National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN271201700006I; Ref. No. N01TR-17-2201.